{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 448072389
| IUPAC_name = 1-[1-[(2-Chlorophenyl)methyl]pyrrol-2-yl]-2-[di(butan-2-yl)amino]ethanol
| image = Viminol2DACS.svg
| width = 180

<!--Clinical data-->
| tradename = Dividol
| Drugs.com = {{drugs.com|international|viminol}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!-- Schedule I -->
| legal_UK = <!-- Unscheduled  -->
| legal_US = Not FDA approved<!-- Most likely Schedule I -->
| legal_status = OTC in Brazil{{cn|date=April 2017}}
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 21363-18-8
| ATC_prefix = N02
| ATC_suffix = BG05
| PubChem = 65697
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 2104940
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = TPV54G6XBG
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07295
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 59125

<!--Chemical data-->
| C=21 | H=31 | Cl=1 | N=2 | O=1 
| smiles = CCC(C)N(C(C)CC)CC(O)C1=CC=CN1CC2=CC=CC=C2Cl
| synonyms = Dividol, viminolo, diviminol
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI          = 1S/C21H31ClN2O/c1-5-16(3)24(17(4)6-2)15-21(25)20-12-9-13-23(20)14-18-10-7-8-11-19(18)22/h7-13,16-17,21,25H,5-6,14-15H2,1-4H3
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey       = ZILPIBYANAFGMS-UHFFFAOYSA-N
}}

'''Viminol''' (marketed under the [[brandname]] '''Dividol''') is an [[opioid]] [[analgesic]] developed by a team at the drug company [[Zambon]] in the 1960s.<ref>{{cite web | url=http://www.google.com/patents/US3539589 | title=US Patent 3539589 - 1-(α-PYRRYL)-2-AMINO ETHANOLS | work=Whitefin Holding Sa | date=10 November 1970 | author=Uberto M. Teotino, Davide Della Bella}}</ref> Viminol is based on the α-pyrryl-2-aminoethanol structure, unlike any other class of opioids.<ref>{{cite journal | title=[Chromatographic separation of diastereoisomers of aminoalcohol salts and their densitometric determination] | author=A. M. Contri | journal=Il Farmaco | date=April 1981 | volume=36 | issue=4 | pages=215–222 | pmid=6894429 | language=Italian}}</ref><ref>{{cite journal | title=Psychopharmacological properties of the viminol-p-hydroxybenzoate. | author=J. M Neto, J.E. Murad, S.S. Monteiro | journal=Revista Brasileira de Pesquisas Medicas e Biologicas | date=December 1977 | volume=10 | issue=6 | pages=361–368 | pmid=609773}}</ref>

Viminol has both [[antitussive]] (cough suppressing) and [[analgesic]] (pain reducing) effects. Viminol has additional effects similar to other opioids including [[sedation]] and [[euphoria]].{{cn|date=April 2017}}  It has six different [[stereoisomer]]s which have varying properties. Four are inactive, but the 1''S''-(''R'',''R'')-disecbutyl isomer is a [[mu opioid receptor|μ-opioid]] full agonist around 5.5 times more potent than [[morphine]] and the 1''S''-(''S'',''S'')-disecbutyl isomer is an [[receptor antagonist|antagonist]].<ref>{{cite web | url=https://www.google.com/patents/US3857857 | title=US Patent 3857857 - Stereoisomers of 1(1'(-O-Chlorobenzyl)-2'-Pyrryl)-2-Disec.Butylamino-Ethanol | work=Whitefin Holding Sa | date=31 December 1974 | author=Davide Della Bella, Carlo Veneziani Bresso, Dario Chiarnio Monza, Uberio Maria Tiotino}}</ref><ref>{{cite journal | url=http://www.sciencedirect.com/science/article/pii/0091305784901011 | title=The discriminative stimulus properties of the R2 isomer of viminol | author=Jennifer E. Shook, Mary Jeanne Kallman, William L. Dewey | journal=Pharmacology Biochemistry and Behavior | date=January 1984 | volume=20 | issue=1 | pages=59–62 | doi=10.1016/0091-3057(84)90101-1 | pmid=6546450}}</ref> Since vimonol is supplied as a [[racemic]] mixture of isomers, the overall effect is a mixed [[agonist–antagonist]] profile similar to that of opioids such as [[pentazocine]], although with somewhat fewer side effects.<ref>{{cite journal | title=Viminol R2 analgesic activity in patients with postoperative pain: comparison with pentazocine. | author=M. Cinelli, V. Costa, G. P. Ventresca, E. Lodola | journal=International Journal of Clinical Pharmacology, Therapy, and Toxicology | year=May 1986 | volume=24 | issue=5 | pages=232–235 | pmid=3525423}}</ref>

==Side effects==
Side effects are similar to other opioids, and can include:{{medcn|date=April 2017}}

* [[Itching]]
* [[Nausea]]
* [[Sedation]]
* [[Respiratory depression]] - can be potentially life-threatening

However, since viminol is supplied as a racemic mixture of agonist and antagonist isomers, the [[abuse potential]] and respiratory depression tends to be less than that of μ-opioid full agonist drugs.{{medcn|date=April 2017}}

[[Substance dependence|Drug dependence]] may occur.<ref>{{cite journal | doi = 10.1080/14659890701237124| title = Dependence on Viminol| journal = Journal of Substance Use| volume = 12| issue = 4| pages = 301| year = 2009| last1 = Turkiewicz| first1 = G.| last2 = Baltieri| first2 = D. A.}}</ref>

==Related compounds==
Later work showed that replacing the chlorine atom with an fluorine atom or with a [[trifluoromethyl]] group produced a compound with twice the potency and half the acute toxicity.<ref>{{cite web | url=http://www.google.com/patents/US4148907 | title=US Patent 4148907 - Stereoisomers of 1-(1'benzyl-2'pyrryl)-2-di-sec.-butylaminoethanol and pharmaceutical compositions comprising same | work=Etablissement Viridis | date=10 April 1979 | author=Franco Conti}}</ref> A later team at Zambon found that one isomer of a [[2-Pyrrolidone|pyrrolidone]] [[structural analog|analog]] is 318 times as potent as morphine in its analgesic activity in animal studies.<ref>{{cite web | url=http://www.google.com/patents/US4960788 | title=US Patent 4960788 - Pyrrolidone-2 compounds and their use for central analgesic activity | work=Zambon Group S.P.A. | date=2 October 1990 | author=Angelo Carenzi, Dario Chiarino, Davide Della Bella, Gian Carlo Grancini, Carlo Veneziani}}</ref> A number of related compounds were also found to be active, allowing a [[Quantitative structure–activity relationship|QSAR model]] to be constructed.

{{Multiple image
| align  = left
| direction  = horizontal
| image1 = Viminol trifluoromethyl derivative.svg
| caption1 = Trifluoromethyl analog
| image2 = Viminol pyrrolidone derivative.svg
| caption2 = Pyrrolidone analog
}}
{{clear-left}}

== References ==
{{Reflist|2}}

{{Opioidergics}}

[[Category:Opioids]]
[[Category:Pyrroles]]
[[Category:Alcohols]]
[[Category:Chloroarenes]]
[[Category:Mu-opioid agonists]]